Browse News

Found 37 articles

• Revolo Biotherapeutics Presents New Data Demonstrating Long-Lasting Effect of ‘1104 in a Food Allergy Model at the 2023 AAAAI Annual Meeting

  2/28/2023

  Revolo Biotherapeutics (“Revolo Bio” or the “Company”) today announced that it has presented new preclinical data in an oral presentation at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting, which was held February 24-27 in San Antonio, Texas.

• Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy

  2/6/2023

  Revolo Biotherapeutics today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, which is being held February 24-27 in San Antonio, Texas.

• Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease

  1/5/2023

  Revolo Biotherapeutics announced that it has completed enrollment and has fully randomized all patients in a Phase 2a clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with allergic disease.

• Revolo Biotherapeutics to Present at TIDES Europe 2022

  11/14/2022

  Revolo Biotherapeutics announced that it will be participating in the TIDES Europe 2022 Conference on Oligonucleotide & Peptide Therapeutics, being held virtually and in-person in Vienna, Austria, from November 16-18.

• Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the StudyTopline data anticipated in early 2023

  11/9/2022

  Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).

• Revolo Biotherapeutics Awarded Patent for ‘1104 in Acute Treatment of Relapsing Remitting Conditions

  11/2/2022

  Revolo Biotherapeutics announced that the U.S. Patent and Trademark Office issued US Patent No. 11,479,585 on October 25, 2022, which covers IRL201104 and related peptides in methods related to the acute treatment of relapsing remitting conditions.

• Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

  9/16/2022

  Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment taking place in Basel, Switzerland from September 21-22.

• Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic EsophagitisTopline data anticipated around year-end 2022

  9/12/2022

  Revolo Biotherapeutics (“Revolo” or the “Company”), today announced that it has completed enrollment and has fully randomized all patients in a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).

• Revolo Biotherapeutics to Present at the Baird 2022 Global Healthcare Conference

  9/8/2022

  Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Baird 2022 Global Healthcare Conference being held in New York, NY, from September 13-14.

• Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

  9/7/2022

  Oncolytics Biotech® Inc. announced the appointment of Jonathan Rigby to its Board of Directors.

• Revolo Biotherapeutics Awarded Innovation Passport for ‘1805 in the United Kingdom for the Treatment of Moderate to Severe Rheumatoid Arthritis

  7/14/2022

  Revolo Biotherapeutics today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the Medicines and Healthcare products Regulatory Agency (MHRA) for its immune-resetting drug candidate, ‘1805, for the treatment of patients with moderately to severely active Rheumatoid Arthritis (RA).

• Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings

  5/16/2022

  Revolo Biotherapeutics announced that the Company will be delivering presentations at two upcoming medical meetings: the American Thoracic Society International Conference and the Treg Summit.

• Revolo Biotherapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

  5/5/2022

  Revolo Biotherapeutics announced that its management team will participate in the LifeSci Partners Immunology & Inflammation Symposium being held virtually May 10-11, 2022.

• Revolo Biotherapeutics to Participate at SVB Leerink Biopharma Private Company Connect

  3/24/2022

  Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced that its management team will be attending the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.

• Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome

  2/25/2022

  Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data will be presented in a poster at the 2022 American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting.

• Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

  2/4/2022

  Revolo Biotherapeutics today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to commence two Phase 2 clinical trials to evaluate its immune-resetting drug candidate.

• 

  CEO to CEO: Tips for First-time Founders

  1/11/2022

  BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders.
• 

  Biopharma Executive Perspectives on 2022

  1/10/2022

  BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.

• Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors

  12/27/2021

  Revolo Biotherapeutics today announced the appointment of industry veteran Tunde Otulana, M.D., to its Board of Directors.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.